In this article, we will be taking a look at the 9 Most Undervalued Healthcare Stocks to Buy Now.
On April 17, Matt Powers, managing partner at Powers Advisory Group, appeared on CNBC’s Squawk Box to discuss the forces shaping current market behavior. The latest market response to global concerns, according to him, was a “textbook” V-shaped move, with a fast sell-off and a quick comeback. Notably, despite a war headline and a sharp increase in oil prices, the S&P 500 reached its highs in around 15 trading days. The market showed underlying strength and tenacity as it hardly approached the correction area. Powers claimed that until additional geopolitical escalations occur, a large portion of the macro risk had already been priced in, indicating a near-term bottom. However, he stressed that markets are still very susceptible to news, especially when it comes to oil, geopolitics, and the timing of the Federal Reserve.
The first quarter has been characterized by this volatility, as the S&P 500 has fluctuated between all-time highs and a decline. Investors are uneasy due to worries about high valuations, economic instability brought on by tensions in the Middle East, and inflation brought on by growing energy prices. Capital has started to shift away from large-cap technology equities in reaction. John Stoltzfus of Oppenheimer, meanwhile, sees this as a more comprehensive diversification strategy in which investors reallocate gains across industries rather than a retreat from technology.
Traditionally a defensive strategy, healthcare has found it difficult to profit from this change. Due to pressure from post-COVID earnings normalization and policy-related valuation concerns, the sector is down around 4% so far this year, trailing a flat broader index. JPMorgan analysts saw evidence of stabilization despite slower earnings growth over the previous five years, indicating that the worst may be behind us.
At the same time, industry fundamentals are being strengthened by increased merger and acquisition activity. This has raised awareness of inexpensive healthcare stocks, especially those backed by insider purchases, which are frequently seen as a powerful signal in an industry that is influenced by changes in clinical, regulatory, and mood. Institutional investors echo this optimism, supported by Deloitte’s February 16, 2026, Global Health Care Outlook, which highlights a sector navigating short-term challenges but positioned for long-term growth, with over 70% of non-US executives expecting higher revenues and profits.
With that said, let’s take a look at the most undervalued stocks.
Our Methodology
For our methodology, we screened for stocks with a P/E below 15 and positive upside. From the filtered list, we picked stocks with the most recent developments and news and ranked them according to their PE ratios.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Here is our list of the 9 most undervalued healthcare stocks to buy now.
9. Elevance Health, Inc. (NYSE:ELV)
PE Ratio: 13.02
Elevance Health, Inc. (NYSE:ELV) is one of the most undervalued stocks on this list.
TheFly reported on April 20 that Jefferies analyst David Windley revised his outlook on ELV, trimming the firm’s price target to $391 from $395 while maintaining a Buy rating on the stock. The adjustment follows a detailed evaluation of health insurance offerings within the Health Insurance Exchange market. Based on this deeper analysis, the firm updated its financial projections across its managed care coverage, reflecting refined assumptions tied to plan dynamics and market conditions in the exchange segment.
Separately, earlier on March 31, Elevance Health, Inc. announced a set of senior leadership changes spanning its Health Benefits segment and Carelon services division to support operational execution and long-term growth. The restructuring is intended to improve coordination across business units, enhance efficiency, and accelerate decision-making as the company expands its services platform.
Carelon, which delivers healthcare, pharmacy, behavioral, and data-driven solutions to a large consumer base, remains a key focus of this strategy. The updated leadership structure also aims to strengthen integration with the Health Benefits business, enabling more aligned offerings that improve care outcomes, reduce costs, and simplify the overall healthcare experience for members while supporting sustained enterprise performance.
Elevance Health, Inc. is a U.S. health company providing managed care and health solutions to over 119 million people. It operates across commercial, Medicare, and Medicaid markets through brands like Anthem Blue Cross Blue Shield, WellPoint, and Carelon.
8. The Cigna Group (NYSE:CI)
PE Ratio: 12.48
The Cigna Group (NYSE:CI) is one of the most undervalued stocks to invest in.
TheFly reported on April 20 that Jefferies reaffirmed its Buy recommendation on CI while slightly reducing its price objective from $333 to $330 after revising its outlook for managed care companies based on a detailed review of Health Insurance Exchange plan offerings.
Additionally, on April 16, The Cigna Group Foundation announced the expansion of its Impact Fund into Memphis, aiming to support local nonprofits working to improve community health outcomes. Eligible organizations can apply for funding of up to $250,000 distributed over two years to advance initiatives focused on increasing access to primary healthcare services and promoting nutrition, healthy food availability, and lifestyle improvements. Applications must be submitted by May 15, 2026, with selected groups entering grant terms beginning December 1, 2026, through December 1, 2028.
In addition to financial support, participating nonprofits will collaborate with health experts and Foundation representatives through annual meetings to share progress and strategies. The initiative builds on prior investments targeting social drivers of health and reflects a continued commitment to addressing healthcare access challenges, including provider shortages, transportation barriers, and limited availability of affordable, nutritious food in underserved Memphis communities.
The Cigna Group is a global health services and insurance company based in Connecticut, serving over 180 million customer relationships. It operates through Cigna Healthcare and Evernorth Health Services, offering health benefits, pharmacy, and care solutions.
7. Organon & Co. (NYSE:OGN)
PE Ratio: 12.28
Organon & Co. is one of the most undervalued healthcare stocks to buy now.
TheFly reported on April 10 that Evercore ISI pointed to media reports suggesting that Sun Pharmaceutical may be nearing a $12 billion offer for OGN, while noting the company described the claims as speculative with no confirmable developments. The firm indicated that regardless of whether a transaction materializes, the situation supports improving valuation sentiment across the specialty pharmaceutical segment, particularly given Organon’s reputation as one of the more challenged players in the group.
Adding to its business developments, Organon & Co. announced on April 15 that its VTAMA (tapinarof) cream, 1%, received a strong endorsement in the 2026 pediatric atopic dermatitis guidelines issued by the American Academy of Dermatology.
The treatment was recognized as the only non-steroidal topical option supported by high-certainty clinical evidence for use in children aged two years and older across all disease severities. The recommendation was supported by data from late-stage clinical trials, reinforcing the therapy’s safety and effectiveness profile. The updated guidelines provide clinicians with structured, evidence-backed direction for managing pediatric skin conditions, highlighting the importance of tailored treatment approaches for younger patients.
Organon & Co. is a global healthcare company spun off from Merck in 2021, focused on women’s health, biosimilars, and established medicines. It is based in New Jersey and operates in over 140 countries.
6. Bio-Rad Laboratories, Inc. (NYSE:BIO)
PE Ratio: 10.98
Bio-Rad Laboratories, Inc. (NYSE:BIO) is among the most undervalued stocks to invest in.
TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from $375 to $300. The revision reflected concerns that the company’s process chromatography segment is unlikely to regain strong growth or margin expansion, despite being a key driver of performance. The outlook was also weighed down by continued uncertainty in Bio-Rad’s diagnostics operations in China, adding further pressure to near-term expectations for the business.
More recently, on April 14, Bio-Rad Laboratories, Inc. expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies by introducing multiple new highly specific antibody products targeting a range of biotherapeutic drugs, including treatments such as Evenity, Crysvita, Taltz, Empliciti, Sarclisa, Beyfortus, and Imjudo, along with a newly developed antibody for Trulicity.
The company also introduced its first antibody set designed to detect Fc region YTE mutations, supporting more advanced analysis of modified therapeutic antibodies. These additions are intended to improve the accuracy of pharmacokinetic and anti-drug antibody testing used in drug development and monitoring. The new offerings broaden BIO’s capabilities in supporting biologic and biosimilar research with more precise and adaptable bioanalytical tools.
Bio-Rad Laboratories, Inc. is a global life science company founded in 1952 and based in California. It develops and supplies tools, instruments, and diagnostics for molecular biology, protein research, and clinical laboratory testing.
5. Inspire Medical Systems, Inc. (NYSE:INSP)
PE Ratio: 10.64
Inspire Medical Systems, Inc. (NYSE:INSP) is among the most undervalued stocks to invest in.
TheFly reported on April 15 that Truist Financial reduced its price target for INSP from $70 to $64 while maintaining a Hold stance on the stock. The adjustment was made within a broader outlook on MedTech ahead of first-quarter results, with expectations that performance may meet or slightly exceed cautious investor sentiment around procedure volumes. However, the firm noted that the current valuation discount versus peers appears warranted due to near-term growth uncertainty, particularly linked to slowing domestic expansion and ongoing reimbursement-related challenges.
Similarly, a day earlier on April 14, Royal Bank of Canada revised its outlook on Inspire Medical Systems, Inc. and lowered its price target from $68 to $56 while maintaining a Sector Perform rating. This update also came as part of a broader MedTech sector review ahead of first-quarter earnings. Despite acknowledging stable underlying demand conditions and generally solid fundamentals with no signs of major market disruption, the firm highlighted that recent sentiment-driven weakness may be overstated. At the same time, it pointed to operational pressures affecting utilization and new center growth, including reimbursement coding challenges and delayed patient progression related to GLP-1 therapy trends, which limit near-term visibility across upcoming quarters.
In separate news, Inspire Medical Systems, Inc. will report its Q1 2026 results on May 4.
Inspire Medical Systems, Inc. is a medical technology company based in Minneapolis that develops implantable neurostimulation therapy for obstructive sleep apnea. It’s an FDA-approved device that stimulates the hypoglossal nerve as an alternative to CPAP treatment.
4. MiMedx Group, Inc. (NASDAQ:MDXG)
PE Ratio: 10.00
MiMedx Group, Inc. (NASDAQ:MDXG) is among the most undervalued stocks.
TheFly reported on April 20 that Citizens Financial Group lowered its price target on MDXG from $10 to $7 while maintaining an Outperform rating. The update noted that the company is pursuing significant expense reductions expected to cut annual operating costs by roughly $40 million. However, near-term performance remains under pressure due to slow recovery trends and ongoing reimbursement-related challenges in the wound care market, which continue to weigh on revenue growth. Despite these headwinds, the firm maintained a positive longer-term view, citing MDXG’s strong clinical evidence base, established operational network, and adaptability across evolving care environments.
Earlier on April 16, MiMedx Group, Inc. announced a restructuring program aimed at lowering operating costs and focusing resources on growth priorities. The initiative is designed to streamline operations and improve efficiency across the business. As part of the changes, the company eliminated the Chief Operating Officer role, previously held by Ricci Whitlow.
The corporation’s Management indicated that further details regarding the restructuring and its financial impact would be shared alongside the first-quarter 2026 earnings discussion during the upcoming conference call later in April, where overall operating performance will also be addressed.
MiMedx Group, Inc. is a regenerative medicine company specializing in placental biologics. It develops and markets human tissue-based products used for advanced wound care and surgical healing applications.
3. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
PE Ratio: 9.60
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the most undervalued healthcare stocks to buy now.
TheFly reported on April 7 that RBC Capital Markets revised its outlook on ACAD, lowering its price target from $30 to $29 while keeping an Outperform rating. The adjustment was included in a broader Biotech sector preview ahead of first-quarter results. The firm noted that seasonal pressures such as reimbursement adjustments, fewer operating days, and adverse weather conditions could weigh on near-term performance, particularly for newly launched and clinic-dependent products. However, it also highlighted that renewed merger and acquisition activity and greater clarity on limited impacts from pricing policy changes may help balance short-term volatility and support a constructive sector outlook.
On the same day, ACADIA Pharmaceuticals Inc. announced the U.S. launch of Daybue Stix, an oral formulation of trofinetide now widely accessible for treating Rett syndrome in both adults and children aged two years and older.
The newly introduced version, previously cleared by the U.S. Food and Drug Administration in December 2025, delivers the same therapeutic effectiveness and safety profile as the original oral solution. It is designed to be bioequivalent while offering improved patient convenience through greater flexibility in dosing volume and taste options, supporting easier administration for individuals living with Rett syndrome.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego focused on CNS disorders and rare diseases. It is known for developing NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome.
2. Galapagos NV (NASDAQ:GLPG)
PE Ratio: 5.06
Galapagos NV (NASDAQ:GLPG) is among the most undervalued stocks to invest in.
TheFly reported on April 7 that RBC Capital Markets adjusted its outlook on GLPG, reducing its price target from $33 to $28 while maintaining a Sector Perform rating. The update was included in a broader Biotech sector preview ahead of first-quarter earnings.
The firm cited expected seasonal pressures such as reimbursement resets, gross-to-net dynamics, and fewer selling days, which could be further affected by weather-related disruptions in early-stage and clinic-based product activity. At the same time, it noted that improving merger and acquisition activity and clearer expectations around drug pricing policy impacts may help offset near-term volatility and support a more stable sector environment.
Additionally, earlier on March 31, Galapagos NV and Gilead Sciences entered a binding framework related to Gilead’s acquisition of Ouro Medicines, a private biotech focused on T-cell engager therapies for autoimmune conditions. The agreement outlines expanded collaboration rights, including access to select Ouro programs such as gamgertamig, alongside provisions for shared development responsibilities, milestone-based payments, and future royalty structures.
It also includes arrangements for operational asset transfer and funding flexibility for GLPG, allowing independent capital deployment and potential share repurchases, while establishing joint participation in advancing autoimmune-focused research and clinical development programs.
Galapagos NV is a Belgium-based biotechnology company focused on developing innovative treatments in immunology and oncology. It works on small molecules and CAR-T cell therapies using a decentralized manufacturing approach.
1. Novavax, Inc. (NASDAQ:NVAX)
PE Ratio: 3.29
Novavax, Inc. (NASDAQ:NVAX) tops our list of the most undervalued stocks.
TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy rating. The update reflected expectations that ongoing shareholder activism focused on governance and cost structure could lead to changes in board composition and additional improvements to the company’s balance sheet.
Separately, on April 18, Sanofi and Novavax, Inc. reported results from the COMPARE Phase 4 clinical trial, the first direct head-to-head study assessing tolerability between protein-based Nuvaxovid and an mRNA COVID-19 vaccine, mNEXSPIKE developed by Moderna. The randomized, double-blind study demonstrated that Nuvaxovid produced significantly lower systemic reactogenicity across all key measured outcomes, indicating fewer expected post-vaccination side effects compared with the comparator vaccine.
Findings were presented at a major infectious disease conference in Munich, Germany. The results reinforce the established safety and tolerability profile of Nuvaxovid and are intended to support broader confidence in the vaccine. They also align with ongoing commercialization efforts led by Sanofi for the upcoming vaccination season, with the data potentially contributing to improved public acceptance and uptake of protein-based COVID-19 vaccination options.
Novavax, Inc. is a biotechnology company based in Maryland that develops vaccines for infectious diseases. It uses recombinant protein nanoparticle technology and its Matrix-M adjuvant to enhance immune response.
READ NEXT: 10 Best Mid Cap Stocks to Invest In According to Billionaires and 10 Best Cheap Stocks Under $10 to Buy in April.
